Amgen Inc. again may face concerns about damage to orphan drug incentives when its proposed biosimilar of Genentech Inc.'s Avastin (bevacizumab) comes before the US FDA's Oncologic Drugs Advisory Committee.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?